Regulus Therapeutics CFO sells shares worth $55,333

2 days ago · In recent transactions filed with the Securities and Exchange Commission, Crispina Calsada, Chief Financial Officer of Regulus Therapeutics Inc . (NASDAQ:RGLS), sold shares totaling $55,333. The ...

$55333
OFF

Regulus Therapeutics CFO Sells Shares Worth $55,333

1 week from now

investing.com

$55333
OFF

Regulus Therapeutics CFO Sells Shares Worth $55,333

1 week from now

3 days ago · In recent transactions filed with the Securities and Exchange Commission, Crispina Calsada, Chief Financial Officer of Regulus Therapeutics Inc . (NASDAQ: RGLS), sold shares …

investing.com

$55333
OFF

Regulus Therapeutics CFO Sells Shares Worth $55,333

1 week from now

In recent transactions filed with the Securities and Exchange Commission, Crispina Calsada, Chief Financial Officer of Regulus Therapeutics Inc . (NASDAQ: RGLS), sold shares totaling …

investing.com

$55333
OFF

Regulus Therapeutics CFO Sells Shares Worth $55,333

1 week from now

3 days ago · In recent transactions filed with the Securities and Exchange Commission, Crispina Calsada, Chief Financial Officer of Regulus Therapeutics Inc . (NASDAQ: RGLS), sold shares …

investing.com

$55333
OFF

Regulus Therapeutics Executives Sell Shares For Tax Obligations

1 week from now

2 days ago · Crispina Calsada, Chief Financial Officer, sold 43,804 shares across January 13 and 14, 2025, at the same price per share, for a total of $55,333, and now directly owns 45,478 …

tradingview.com

$55333
OFF

Insider Trading News Today - Investing.com

1 week from now

Regulus Therapeutics CFO sells shares worth $55,333. In recent transactions filed with the Securities and Exchange Commission, Crispina Calsada, Chief Financial Officer of Regulus …

investing.com

$1.19
OFF

Who Owns Regulus Therapeutics? - WallStreetZen

1 week from now

Chief Financial Officer: 2024-01-18: 5,468: $1.19: $6.51k Sell. Joseph P. Hagan: Chief Executive Officer: 2024-01-18: 14,580: ... Ravi Viswanathan's Regulus Therapeutics shares are currently …

wallstreetzen.com

$160494
OFF

Regulus Therapeutics CEO Sells Shares Worth $160,494

1 week from now

3 days ago · This follows a conversation with Regulus Therapeutics’ CEO and President, focusing on the company’s clinical candidate RGLS8429. The company is on track for an End of Phase …

investing.com

$160494
OFF

Regulus Therapeutics CEO Sells Shares Worth $160,494

1 week from now

Regulus Therapeutics CEO sells shares worth $160,494. View all comments (0) 0. RGLS-These transactions were conducted to cover tax withholding obligations related to the vesting of …

investing.com

$160494
OFF

Regulus Therapeutics CEO Sells Shares Worth $160,494

1 week from now

2 days ago · Furthermore, Jones Trading has reiterated its Buy rating on Regulus, with a steady price target of $8.00. This follows a conversation with Regulus Therapeutics' CEO and …

investing.com

$58873
OFF

Christopher Aker Biography And Net Worth - InsiderTrades.com

1 week from now

Jul 25, 2024 · Mr. Aker owns 41,754 shares of Regulus Therapeutics stock worth more than $58,873 as of January 12th. This net worth evaluation does not reflect any other assets that …

insidertrades.com

FAQs about Regulus Therapeutics CFO sells shares worth $55,333 Coupon?

Does Regulus Therapeutics Inc (RGLS) have company insights?

RGLS does not have Company Insights Find the latest Regulus Therapeutics Inc. (RGLS) stock quote, history, news and other vital information to help you with your stock trading and investing. ...

What is Regulus Resources Inc?

Regulus Resources Inc is a Canadian based firm that is engaged in the acquisition, exploration, and development of exploratory properties until it generates commercial production. The company holds a portfolio of properties located in Peru, Argentina, Chile, the USA, and Canada, in which it holds a majority part of the interest. ...

What does Regulus Therapeutics do?

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. ...